Publicacións nas que colabora con Javier Ampuero Herrojo (14)

2024

  1. Letter to the Editor: Serum Identification of At-Risk MASH: The Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF)

    Hepatology

  2. Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia

  3. Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)

    Hepatology, Vol. 79, Núm. 1, pp. 135-148

  4. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

2022

  1. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

    Human Molecular Genetics, Vol. 31, Núm. 23, pp. 3945-3966

  2. Global multi-stakeholder endorsement of the MAFLD definition

    The Lancet Gastroenterology and Hepatology

2021

  1. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

  2. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

2020

  1. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5

  2. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

  3. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

    Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25

2018

  1. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity

    Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 11-12, pp. 1260-1270